With a median overall survival of only 11 months, intrahepatic cholangiocarcinoma (IHC) warrants more effective therapies. Researchers recently discovered that a regimen of hepatic arterial infusion of floxuridine plus systemic gemcitabine and oxaliplatin produces promising outcomes in patients with unresectable IHC. In this phase 2 clinical trial, 38 patients with histologically confirmed, unresectable IHC were enrolled and treated. Participants with resectable metastatic disease to regional ly...
Biliary tract cancers have a dismal prognosis, with five-year survival rates ranging from 5% to 15%. In their publication in JAMA Oncology , Sarah S. Jackson, PhD, and colleagues report that aspirin increases survival in biliary tract cancers , including gallbladder cancer, cholangiocarcinoma, ampulla of Vater cancer, and overlapping lesions of the biliary tract. In this interview with i3 Health, Dr. Jackson discusses the potential ramifications of her study's findings. What led you to pursue ...
Researchers have now revealed that aspirin can increase the dismal survival chances for biliary tract cancers. Because these rare diseases may not produce symptoms until the later stages, 60% to 70% of patients with biliary tract cancers present with later-stage disease. Less than 10% have resectable tumors at the time of diagnosis, and 50% present with lymph node metastasis. As a result, the median survival is under a year, with five-year survival rates ranging from 5% to 15%. "There is a cri...
Based on REACH-2, a phase 3 trial, ramucirumab (Cyramza®, Eli Lilly) was granted FDA approval for patients with advanced hepatocellular carcinoma, a-fetoprotein concentrations of ≥400 ng/mL, and who have been previously treated with sorafenib. Ramucirumab had already been FDA approved for treatment of advanced gastric cancer, non-small cell lung cancer, and metastatic colorectal cancer. This drug works as a monoclonal antibody that targets and binds to the vascular endothelial growth factor rece...
In a single pathogen sensor, researchers have found both a potential therapeutic target and a possible way to improve the efficacy of current immune checkpoint blockade therapies for hepatocellular carcinoma (HCC), the most common type of primary liver cancer. Since HCC is associated with chronic inflammation, and NLRP12, a cytosolic pathogen sensor, is a negative regulator of inflammation, researchers at the University of Texas (UT) Southwestern Medical Center decided to investigate its role ...